Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 360


Neuroinflammation and comorbidities are frequently ignored factors in CNS pathology.

Sandu RE, Buga AM, Uzoni A, Petcu EB, Popa-Wagner A.

Neural Regen Res. 2015 Sep;10(9):1349-1355. Review.


Antidepressant efficacy and side-effect burden: a quick guide for clinicians.

Santarsieri D, Schwartz TL.

Drugs Context. 2015 Oct 8;4:212290. eCollection 2015. Review.


Targeting inflammation to influence mood following spinal cord injury: a randomized clinical trial.

Allison DJ, Ditor DS.

J Neuroinflammation. 2015 Nov 6;12(1):204. doi: 10.1186/s12974-015-0425-2.


Anhedonia and the brain reward circuitry in depression.

Heshmati M, Russo SJ.

Curr Behav Neurosci Rep. 2015 Sep;2(3):146-153. Epub 2015 Jul 12.


Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study).

Trevithick L, McAllister-Williams RH, Blamire A, Branton T, Clark R, Downey D, Dunn G, Easton A, Elliott R, Ellwell C, Hayden K, Holland F, Karim S, Lowe J, Loo C, Nair R, Oakley T, Prakash A, Sharma PK, Williams SR, Anderson IM.

BMC Psychiatry. 2015 Oct 21;15(1):257. doi: 10.1186/s12888-015-0641-4.


Systematic Review of the Neurobiological Relevance of Chemokines to Psychiatric Disorders.

Stuart MJ, Singhal G, Baune BT.

Front Cell Neurosci. 2015 Sep 10;9:357. doi: 10.3389/fncel.2015.00357. eCollection 2015. Review.


Severity of Depression Predicts Remission Rates Using Transcranial Magnetic Stimulation.

Grammer GG, Kuhle AR, Clark CC, Dretsch MN, Williams KA, Cole JT.

Front Psychiatry. 2015 Sep 1;6:114. doi: 10.3389/fpsyt.2015.00114. eCollection 2015.


Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial.

Husain MI, Chaudhry IB, Rahman RR, Hamirani MM, Qurashi I, Khoso AB, Deakin JF, Husain N, Young AH.

Trials. 2015 Sep 15;16:410. doi: 10.1186/s13063-015-0933-5.


Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology.

Parrott JM, O'Connor JC.

Front Psychiatry. 2015 Aug 20;6:116. doi: 10.3389/fpsyt.2015.00116. eCollection 2015. Review.


Implementing measurement-based care (iMBC) for depression in community mental health: a dynamic cluster randomized trial study protocol.

Lewis CC, Scott K, Marti CN, Marriott BR, Kroenke K, Putz JW, Mendel P, Rutkowski D.

Implement Sci. 2015 Sep 7;10:127. doi: 10.1186/s13012-015-0313-2.


Acute Treatment with a Novel TRPC4/C5 Channel Inhibitor Produces Antidepressant and Anxiolytic-Like Effects in Mice.

Yang LP, Jiang FJ, Wu GS, Deng K, Wen M, Zhou X, Hong X, Zhu MX, Luo HR.

PLoS One. 2015 Aug 28;10(8):e0136255. doi: 10.1371/journal.pone.0136255. eCollection 2015.


Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature.

Kelliny M, Croarkin PE, Moore KM, Bobo WV.

Ther Clin Risk Manag. 2015 Aug 12;11:1193-212. doi: 10.2147/TCRM.S55313. eCollection 2015. Review.


Optimizing the Exercise Prescription for Depression: The Search for Biomarkers of Response.

Medina JL, Jacquart J, Smits JA.

Curr Opin Psychol. 2015 Apr 1;4:43-47.


Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice.

Han C, Wang SM, Lee SJ, Jun TY, Pae CU.

Chonnam Med J. 2015 Aug;51(2):66-80. doi: 10.4068/cmj.2015.51.2.66. Epub 2015 Aug 17. Review.


Modulation of muscarinic system with serotonin-norepinephrine reuptake inhibitor antidepressant attenuates depression in mice.

Singh P, Singh TG.

Indian J Pharmacol. 2015 Jul-Aug;47(4):388-93. doi: 10.4103/0253-7613.161260.


The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.

Zanos P, Piantadosi SC, Wu HQ, Pribut HJ, Dell MJ, Can A, Snodgrass HR, Zarate CA Jr, Schwarcz R, Gould TD.

J Pharmacol Exp Ther. 2015 Oct;355(1):76-85. doi: 10.1124/jpet.115.225664. Epub 2015 Aug 11.


Pharmacological approaches to the challenge of treatment-resistant depression.

Ionescu DF, Rosenbaum JF, Alpert JE.

Dialogues Clin Neurosci. 2015 Jun;17(2):111-26.


Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report.

Singh AB.

Clin Psychopharmacol Neurosci. 2015 Aug 31;13(2):150-6. doi: 10.9758/cpn.2015.13.2.150.


A neurocognitive model for understanding treatment action in depression.

Warren MB, Pringle A, Harmer CJ.

Philos Trans R Soc Lond B Biol Sci. 2015 Sep 19;370(1677):20140213. doi: 10.1098/rstb.2014.0213.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk